(64 days)
Not Found
Not Found
No
The summary describes a standard clinical chemistry test system for measuring LDL cholesterol, which relies on chemical reactions and optical detection, not AI/ML. There are no mentions of AI, ML, image processing, or data-driven algorithms for interpretation or analysis beyond standard calibration and quality control.
No
The device is a diagnostic test system used to measure LDL Cholesterol levels, not to treat a condition or disease.
Yes
The text explicitly states the system is for the "quantitative determination of LDL Cholesterol concentrations in human serum and plasma," which is a diagnostic measurement used in assessing the risk and management of coronary artery disease.
No
The device description explicitly mentions "LDL Cholesterol Reagent, LDL Cholesterol Calibrator, and Assayed HDL/L/L/L Cholesterol Control materials" and their use on "Olympus Family of Clinical Chemistry Analyzers," indicating it includes physical components and is not solely software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the system is for the "quantitative determination of LDL Cholesterol concentrations in human serum and plasma." This involves testing biological samples (serum and plasma) outside of the body (in vitro).
- Components: The system includes reagents, calibrators, and control materials specifically designed for use in a clinical chemistry analyzer to measure a substance in a biological sample.
- Purpose: The purpose is to measure LDL Cholesterol levels, which are used for the "measurement of the LDL Cholesterol concentration in serum and plasma" and play a role in the "development of coronary artery disease." This indicates a diagnostic purpose related to a medical condition.
All of these points align with the definition of an In Vitro Diagnostic device, which is used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes.
N/A
Intended Use / Indications for Use
The Olympus LDL Cholesterol Test System contains LDL Cholesterol Reagent, LDL Cholesterol Calibrator, and Assayed HDL/L/L/L Cholesterol Control materials intended for use on the Olympus Family of Clinical Chemistry Analyzers for the quantitative determination of LDL Cholesterol concentrations in human serum and plasma.
The Olympus LDL Cholesterol Calibrator is a lyophilized human serum intended to provide an LDL concentration of known value for use in calibration of the Olympus LDL Cholesterol Reagent used on the Olympus family of Clinical Chemistry Analyzers.
The Olympus HDL/LDL Cholesterol Control consists of lyophilized human sera. These assayed control sera a designed to monitor the recovery and precision of the Olympus LDL Cholesterol Reagent used on the Olympus family of Clinical Chemistry Analyzers.
LDL Cholesterol levels play a causal role in the development of coronary artery disease and is used for the measurement of the LDL Cholesterol concentration in serum and plasma.
Product codes
LBS, JIT
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Not Found
Key Metrics
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1475 Lipoprotein test system.
(a)
Identification. A lipoprotein test system is a device intended to measure lipoprotein in serum and plasma. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the perimeter. Inside the circle is an abstract symbol resembling an eagle or bird in flight, composed of three curved lines.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
FEB 0 8 2002
Mr. Michael Campbell Manager, Regulatory Affairs/Quality Assurance Olympus America Inc Diagnostic Systems Group 3131 West Royal Lane Irving Texas 75063-3104
Re: K014032
Trade/Device Name: Olympus LDL Cholesterol Test System Regulation Number: 21 CFR 862.1475; 21 CFR 862.1150 Regulation Name: Lipoprotein test system; Calibrator Regulatory Class: Class I; Class II Product Code: LBS; JIT Dated: January 18, 2002 Received: January 22, 2002
Dear Mr. Campbell:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
Page 2 -
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and i additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/odrb/dsma/dsmamain.html".
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory-Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use Statement
510(k) Number (if known): K014032
Device Name:
Olympus LDL Cholesterol Test System Contents: Olympus LDL Cholesterol Reagent Olympus LDL Cholesterol Calibrator Olympus HDL/LDL Cholesterol Control
Indications for Use:
(per 21 CFR 801.109)
The Olympus LDL Cholesterol Test System contains LDL Cholesterol Reagent, LDL Cholesterol Calibrator, and Assayed HDL/L/L/L Cholesterol Control materials intended for use on the Olympus Family of Clinical Chemistry Analyzers for the quantitative determination of LDL Cholesterol concentrations in human serum and plasma.
The Olympus LDL Cholesterol Calibrator is a lyophilized human serum intended to provide an LDL concentration of known value for use in calibration of the Olympus LDL Cholesterol Reagent used on the Olympus family of Clinical Chemistry Analyzers.
The Olympus HDL/LDL Cholesterol Control consists of lyophilized human sera. These assayed control sera a designed to monitor the recovery and precision of the Olympus LDL Cholesterol Reagent used on the Olympus family of Clinical Chemistry Analyzers.
LDL Cholesterol levels play a causal role in the development of coronary artery disease and is used for the measurement of the LDL Cholesterol concentration in serum and plasma.
Sean Ciofin
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K014632
(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)
| Concurrence of CDRH, Office of Device Evaluation (ODE) |
|---|
| -------------------------------------------------------- |
| Prescription Use | OR Over-The-Counter Use |
|---|---|
| ------------------ | ------------------------- |
(Optional Format 1-2-96)